2Q Pharma Results Preview: Novartis And J&J Lead The Pack
Scrip offers some top topics to monitor as second-quarter biopharmaceutical sales and earnings start to be unveiled. First out of the blocks will be Johnson & Johnson and Novartis AG. Recent and coming launches, pricing strategies, M&A and the biosimilar landscape are key themes to watch out for as the duo and other players update at their half-year points.
You may also be interested in...
IPOs are up, hemophilia is driving company pipelines, speculation over Pascal Soriot's career plans drive billions from AstraZeneca's market capitalization, Sanofi signs a $650m vaccine deal, private equity bidders up their offer for Stada and earnings season kicks off. Commercial capsule rounds up recent business news and trends reported by sister publication Scrip.
FDA approved Johnson & Johnson's IL-23 blocker guselkumab July 13; the drug will be priced at an annual wholesale acquisition cost of $58,100, roughly in line with the currently marketed IL-17 blocker Cosentyx.
FDA's Oncologic Drugs Advisory Committee recommends 10-0 the agency approve Novartis' tisagenlecleucel (CTL019) for pediatric leukemia in a panel review that was hailed by some in the industry as historic.